Mather Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Mather Group’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-750	Closed	-$17.8K	–	2136
2024 Q2	$17.8K	Buy	+750	New	+$15.7K	﹤0.01%	1291

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mather Group's SNDX Position: Q3 2024 in Review

Mather Group sold out of Syndax Pharmaceuticals (SNDX) in Q3 2024, closing a stake of 750 shares — an estimated $17.8K sold.

Mather Group first reported a position in SNDX in Q2 2024 and held it in 1 quarter. The position peaked at $17.8K in Q2 2024. 210 funds tracked by Wall St. Rank hold SNDX as of Q3 2024.

Mather Group reported no remaining Syndax Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Mather Group sold 750 Syndax Pharmaceuticals shares in Q3 2024, an estimated $17.8K.
Mather Group first reported a position in Syndax Pharmaceuticals in Q2 2024 and held it in 1 quarter.
Mather Group's Syndax Pharmaceuticals position peaked at $17.8K in Q2 2024.
210 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2024.

Based on Mather Group's 13F filing for Q3 2024, filed 7 Oct 2024.